AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.